Articles related to GLYCEMIC CONTROL

Magnesium plays a crucial role in metabolic health, influencing insulin function and cardiovascular physiology. Addressing magnesium deficiency through dietary changes and supplementation can help manage and prevent metabolic syndrome.

Brazzein, now FDA-approved, emerges as a zero-calorie sweetener potentially safe for diabetic and obese populations, requiring further study to validate its health impacts.

In patients with type 2 diabetes and stage 5 chronic kidney disease, the use of SGLT2 inhibitors is associated with a lower risk of initiating dialysis and experiencing major cardiovascular events, providing a promising therapeutic avenue in a population at elevated risk.

This study highlights the importance of evaluating the nutritional content of plant-based meat substitutes as they compare closely with traditional meats in terms of cardiometabolic health outcomes, with neither showing clear benefits over the other.

The latest research provides evidence that non-sugar sweeteners do not enhance appetite and can lower blood sugar and insulin levels post-consumption, which may be significant in managing metabolic health.

SGLT-2 inhibitors have emerged as a cornerstone in managing HFrEF and CKD, demonstrating substantial reductions in cardiovascular and renal adverse outcomes. This class of medications is reshaping the therapeutic approach in patients with these comorbid conditions, providing a dual benefit that was once considered challenging to achieve.